Details of Drug

Details of Drug

 Drug General Information (ID: D1836)
  Drug Name
Lipoic acid
  Drug Type Small molecule
  Drug Synonymous
Lipoic acid; lipoic acid; 1200-22-2; (R)-lipoic acid; R-(+)-alpha-Lipoic acid; (R)-5-(1,2-Dithiolan-3-yl)pentanoic acid; Heparlipon; Thioctic acid d-form; (R)-(+)-1,2-Dithiolane-3-pentanoic acid; R-alpha-Lipoic acid; (R)-1,2-Dithiolane-3-pentanoic acid; Tioctic Acid; D-Thioctic acid; R-(+)-Thioctic acid; (R)-alpha-Lipoic acid; (R)-(+)-lipoic acid; (R)-6,8-thioctic acid; lipoate; (R)-1,2-Dithiolane-3-valeric Acid; 5-[(3R)-1,2-dithiolan-3-yl]pentanoic acid; (R)-(+)-Lipoate; UNII-VLL71EBS9Z; R-Lipoic acid; INV-144
    Click to Show/Hide
  Disease Class GB61: Chronic kidney disease
  Therapeutic Class Antioxidants
  Structure Could Not Find 2D Structure
3D Structure 2D Structure
  Formula C8H14O2S2
  InChI 1S/C8H14O2S2/c9-8(10)4-2-1-3-7-5-6-11-12-7/h7H,1-6H2,(H,9,10)/t7-/m1/s1
  InChIKey AGBQKNBQESQNJD-SSDOTTSWSA-N
  Canonical SMILES C1CSSC1CCCCC(=O)O
  External Link
Pubchem ID 6112
CAS Number CAS 1200-22-2
CHEBI ID CHEBI:30314
TTD ID D02EVF

Drug-Drug Interaction Network
  Sunburst Graph
AM006  Pharmacodynamic additive effects
BM064  Increased risk of hypoglycemia
  Relation Graph
 Full list of drugs interacting with Lipoic acid
      Pharmacodynamic additive effects
   Increased risk of hypoglycemia Drug Num:  29
Drug ID
 
Drug Name
 Formula Pubchem ID Severity Level Interaction Detail REF
D0811
 
Insulin glargine
 
C267H404N72O78S6
 
118984454 
Minor    Inter Info   
[1], [2], [3]
D0813
 
Insulin human
 
C257H383N65O77S6
 
118984375 
Minor    Inter Info   
[1], [2], [3]
D0814
 
Insulin human (inhalation, rapid acting)
 
C257H383N65O77S6
 
118984375 
Minor    Inter Info   
[1], [2], [3]
D0815
 
Insulin human (isophane)
 
C257H383N65O77S6
 
118984375 
Minor    Inter Info   
[1], [2], [3]
D0816
 
Insulin human (regular)
 
C257H383N65O77S6
 
118984375 
Minor    Inter Info   
[1], [2], [3]
D0817
 
Insulin human (zinc extended)
 
C257H383N65O77S6
 
118984375 
Minor    Inter Info   
[1], [2], [3]
D0818
 
Insulin human (zinc)
 
C257H383N65O77S6
 
118984375 
Minor    Inter Info   
[1], [2], [3]
D0819
 
Insulin lispro
 
C257H389N65O77S6
 
16132438 
Minor    Inter Info   
[1], [2], [3]
D0820
 
Insulin lispro (protamine)
 
C257H389N65O77S6
 
16132438 
Minor    Inter Info   
[1], [2], [3]
D0009
 
Acarbose
 
C25H43NO18
 
41774 
Minor    Inter Info   
[1], [2], [3]
D0013
 
Acetohexamide
 
C15H20N2O4S
 
1989 
Minor    Inter Info   
[1], [2], [3]
D0325
 
Chlorpropamide
 
C10H13ClN2O3S
 
2727 
Minor    Inter Info   
[1], [2], [3]
D0727
 
Glimepiride
 
C24H34N4O5S
 
3476 
Minor    Inter Info   
[1], [2], [3]
D0728
 
Glipizide
 
C21H27N5O4S
 
3478 
Minor    Inter Info   
[1], [2], [3]
D0730
 
Glyburide
 
C23H28ClN3O5S
 
3488 
Minor    Inter Info   
[1], [2], [3]
D0807
 
Insulin aspart (aspart protamine)
 
C256H381N65O79S6
 
118984445 
Minor    Inter Info   
[1], [2], [3]
D0808
 
Insulin aspart (aspart)
 
C256H381N65O79S6
 
118984445 
Minor    Inter Info   
[1], [2], [3]
D0809
 
Insulin degludec
 
C274H411N65O81S6
 
118984462 
Minor    Inter Info   
[1], [2], [3]
D0810
 
Insulin detemir
 
C267H402N64O76S6
 
16137271 
Minor    Inter Info   
[1], [2], [3]
D0812
 
Insulin glulisine
 
C258H384N64O78S6
 
16136701 
Minor    Inter Info   
[1], [2], [3]
D1015
 
Metformin
 
C4H11N5
 
4091 
Minor    Inter Info   
[1], [2], [3]
D1064
 
Miglitol
 
C8H17NO5
 
441314 
Minor    Inter Info   
[1], [2], [3]
D1112
 
Nateglinide
 
C19H27NO3
 
5311309 
Minor    Inter Info   
[1], [2], [3]
D1294
 
Pioglitazone
 
C19H20N2O3S
 
4829 
Minor    Inter Info   
[1], [2], [3]
D1392
 
Repaglinide
 
C27H36N2O4
 
65981 
Minor    Inter Info   
[1], [2], [3]
D1429
 
Rosiglitazone
 
C18H19N3O3S
 
77999 
Minor    Inter Info   
[1], [2], [3]
D1601
 
Tolazamide
 
C14H21N3O3S
 
5503 
Minor    Inter Info   
[1], [2], [3]
D1603
 
Tolbutamide
 
C12H18N2O3S
 
5505 
Minor    Inter Info   
[1], [2], [3]
D1652
 
Troglitazone
 
C24H27NO5S
 
5591 
Minor    Inter Info   
[1], [2], [3]
References
1 Skillman TG, Feldman JM "The pharmacology of sulfonylureas." Am J Med 70 (1981): 361-72. [PMID: 6781341]
2 Konrad T, Bohles HJ, Vicini P, et al "alpha-Lipoic acid treatment decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese patients with type 2 diabetes." Diabetes Care 22 (1999): 280-7. [PMID: 10333946]
3 Gleiter CH, Schreeb KH, Freudenthaler S, et al "Lack of interaction between thioctic acid, glibenclamide and acarbose." Br J Clin Pharmacol 48 (1999): 819-25. [PMID: 10594485]